{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"10"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"9"}]}],"title":"Progression of Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"Number of Participants with Partial Response (PR), Stable Disease (SD), Progression of Disease (POD) Per Response Evaluation Criteria In Solid Tumors Criteria\" (RECIST v1.0) for target lesions and assessed by MRI and/or CT: Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for a Partial Response nor sufficient increase to qualify for Progression of Disease (POD); POD, 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions","groups":[{"description":"Patients receive alvocidib IV over 1 hour and oxaliplatin IV over 2 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Part A (Alvocidib and Oxaliplatin)"},{"description":"Patients receive alvocidib IV over 1 hour, oxaliplatin IV over 2 hours, and leucovorin calcium IV over 2 hours followed by fluorouracil IV continuously over 48 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Part B (Alvocidib and FOLFOX)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Within 3 courses of treatment","title":"Objective Response Rate","type":"PRIMARY","unitOfMeasure":"participants"}